Regentis' GelrinC Demonstrates Near-Complete Cartilage Repair in 24-Month Phase II Study Using Quantitative MOCART Assessment
核心洞察
Regentis Biomaterials published peer-reviewed data in Cartilage journal showing GelrinC (搜索) achieved a mean MOCART score of 88.8 out of 100 at 24 months, indicating near-complete structural cartilage repair.
The company became the first to use MOCART as a predefined endpoint in cartilage repair clinical trials, with FDA acceptance of this objective, quantitative imaging-based assessment approach.
GelrinC (搜索) demonstrated superior performance with osteochondral lesions achieving 94 MOCART score and chondral lesions reaching 86.8, showing ongoing tissue maturation toward hyaline-like cartilage.
Regentis Biomaterials Ltd. has published compelling long-term follow-up data from its Phase II clinical trial of GelrinC (搜索)®, demonstrating exceptional cartilage repair durability at 24 months. The peer-reviewed study, published in the journal Cartilage and led by Prof. Siegfried Trattnig of Vienna University (搜索), represents a significant advancement in objective cartilage regeneration assessment.
Breakthrough MOCART Assessment Methodology
Regentis achieved a world-first by extensively using MOCART (Magnetic Resonance Observation of Cartilage Repair Tissue) as a predefined endpoint in a cartilage repair clinical trial, with U.S. Food and Drug Administration acceptance of this approach. Unlike predominantly subjective clinical endpoints commonly used in cartilage repair studies, Regentis deliberately selected objective, imaging-based endpoints as a rigorous measure of structural repair from the outset.
The company is unique in having predefined MOCART as a prospective imaging and primary endpoint built into the protocol from day one, with MOCART assessments conducted by the Vienna University (搜索)-based team that developed the method, which is widely regarded as the gold standard.
Exceptional Clinical Outcomes
The Phase II study results demonstrated remarkable cartilage regeneration outcomes. The mean MOCART score improved significantly to 88.8 average score out of 100 at 24 months (P < 0.001) for all lesions combined, an indicator consistent with near-complete structural repair.
For specific lesion subtypes at 24 months, chondral lesions achieved a mean MOCART score of 86.8, while osteochondral lesions reached an impressive mean MOCART score of 94. Quantitative MRI showed significant maturation toward hyaline-like cartilage, indicating that two years after treatment, the repaired cartilage appears very close to normal, healthy cartilage based on objective MRI assessment.
Clinical Significance and Competitive Positioning
"We believe, these outcomes position GelrinC (搜索) among the most advanced cartilage repair solutions, demonstrating near-complete long-term morphologic restoration," said Dr. Ehud Geller, Executive Chairman of Regentis. "When we benchmark the few competitor MOCART results, GelrinC far outperforms them."
The imaging data shows ongoing tissue maturation over time, supporting the durability of the repair and establishing GelrinC (搜索) as a leader in long-term durable cartilage repair using objective, quantitative MOCART assessment to demonstrate morphologic outcomes that consistently outperform other treatment modalities.
Regulatory Progress and Market Position
GelrinC (搜索) is currently being evaluated in a pivotal Phase III U.S. Food and Drug Administration investigational device exemption (IDE) study designed to support a future premarket approval (PMA) submission, with 80 patients and two-year follow-up as part of the core study design. Regentis has achieved over 50% enrollment in this pivotal trial.
The cell-free, off-the-shelf hydrogel synchronized erosion and resorbable implant already holds CE Mark approval in the European Union. GelrinC (搜索) offers surgeons and payers an off-the-shelf, ready to use, simple to perform, reliable, and cost-effective procedure that provides patients with a single, 10-minute procedure, faster recovery, sustained pain relief, and functional improvement for more than 4 years, based on clinical study results to date.
Addressing Unmet Medical Need
GelrinC (搜索) aims to address a market of approximately 470,000 cases for cartilage knee repair annually in the U.S. where no effective off-the-shelf, ready to use treatment for focal knee cartilage defects (搜索) is currently available on the market. The Gelrin platform technology, based on synchronized, degradable hydrogel implants, regenerates damaged or diseased tissue including inflamed cartilage and bone through a controlled and synchronous process where surrounding cells regenerate the cartilage.